Alpharetta, GA — Chemence Medical, a world leader in medical cyanoacrylate devices and products, announced the U.S. Federal Drug Administration’s (FDA) 510(k) approval of the company’s redesigned exofin fusion® skin closure system.
Alpharetta, Georgia – February 15, 2016
Chemence Medical, Inc., a manufacturer and distributor of adhesive-based medical devices, announced it received Food and Drug Administration clearance to market and sell Exofin®, a new topical skin adhesive for wound closure. Exofin enters the market as the fastest polymerizing 2-octyl cyanoacrylate topical adhesive available and as the highest viscosity formulation in the industry. Read more